Cellular Biomedicine Inc logo

CBMG - Cellular Biomedicine Inc News Story

$18.24 0.2  1.3%

Last Trade - 22/01/21

Sector
Healthcare
Size
Small Cap
Market Cap £259.6m
Enterprise Value £275.6m
Revenue £236k
Position in Universe 3725th / 6630

BRIEF-Cellular Biomedicine Says Application Accepted By NMPA For Clinical Trial In China For ANTI-BCMA CAR-T

Fri 3rd April, 2020 10:43pm
April 3 (Reuters) - Cellular Biomedicine Group Inc  CBMG.O :
    * CELLULAR BIOMEDICINE - ON MARCH 31, CO'S APPLICATION
ACCEPTED BY
NMPA FOR CLINICAL TRIAL IN CHINA FOR ANTI-BCMA CAR-T FOR
RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Source text: https://bit.ly/2UVysOO
Further company coverage:  CBMG.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.